Portola Pharma (PTLA) Misses Q2 EPS by 5c

Portola Pharma (NASDAQ: PTLA) reported Q2 EPS of ($1.12), $0.05 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $2.3 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94